[HTML][HTML] Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy
Y Park, MJ Kim, Y Choi, NH Kim, L Kim… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Immunotherapy has fundamentally changed the landscape of cancer treatment. However,
only a subset of patients respond to immunotherapy, and a significant portion experience …
only a subset of patients respond to immunotherapy, and a significant portion experience …
Challenges and opportunities in clinical applications of blood-based proteomics in cancer
Simple Summary The traditional approach in identifying cancer related protein biomarkers
has focused on evaluation of a single peptide/protein in tissue or circulation. At best, this …
has focused on evaluation of a single peptide/protein in tissue or circulation. At best, this …
Selective inhibitor of the c-Met receptor tyrosine kinase in advanced hepatocellular carcinoma: no beneficial effect with the use of tivantinib?
S Zhao, W Wu, H Jiang, L Ma, C Pan, C Jin… - Frontiers in …, 2021 - frontiersin.org
Advanced hepatocellular carcinoma (HCC) remains a formidable health challenge
worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The …
worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The …
The role of proteomics and phosphoproteomics in the discovery of therapeutic targets and biomarkers in acquired EGFR-TKI-resistant non-small cell lung cancer
S Moonmuang, A Tantraworasin, S Orrapin… - International Journal of …, 2023 - mdpi.com
The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the
treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded …
treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded …
Mass spectrometry-based multivariate proteomic tests for prediction of outcomes on immune checkpoint blockade therapy: the modern analytical approach
J Grigorieva, S Asmellash, L Net, M Tsypin… - International Journal of …, 2020 - mdpi.com
The remarkable success of immune checkpoint inhibitors (ICIs) has given hope of cure for
some patients with advanced cancer; however, the fraction of responding patients is 15 …
some patients with advanced cancer; however, the fraction of responding patients is 15 …
[HTML][HTML] The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy
SM Lee, S Upadhyay, C Lewanski, S Falk… - European Journal of …, 2019 - Elsevier
Purpose We previously demonstrated that the median survival of patients with poor
prognosis non–small cell lung cancer (NSCLC) considered unfit for first-line platinum …
prognosis non–small cell lung cancer (NSCLC) considered unfit for first-line platinum …
Design and characterization of a novel blood collection and transportation device for proteomic applications
NK Kaiser, M Steers, CM Nichols, H Mellert… - Diagnostics, 2020 - mdpi.com
A major hurdle for blood-based proteomic diagnostics is efficient transport of specimens
from the collection site to the testing laboratory. Dried blood spots have shown utility for …
from the collection site to the testing laboratory. Dried blood spots have shown utility for …
The new and the old: platform cross-validation of immunoaffinity MASS spectrometry versus ELISA for PromarkerD, a predictive test for diabetic kidney disease
PromarkerD is a proteomics derived test for predicting diabetic kidney disease that
measures the concentrations of three plasma protein biomarkers, APOA4, CD5L and IBP3 …
measures the concentrations of three plasma protein biomarkers, APOA4, CD5L and IBP3 …
Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis
TA Leal, AC Argento, K Bhadra… - … medical research and …, 2020 - Taylor & Francis
Objective Timely assessment of patient-specific prognosis is critical to oncology care
involving a shared decision-making approach, but clinical prognostic factors traditionally …
involving a shared decision-making approach, but clinical prognostic factors traditionally …
Blood-Based Cancer Screening/Early Cancer Detection
MI Elewaily - Handbook of Cancer and Immunology, 2023 - Springer
Background: Efficient cancer screening and early cancer diagnosis can significantly
decrease the rate of cancer-related deaths. Currently used measures, such as tissue biopsy …
decrease the rate of cancer-related deaths. Currently used measures, such as tissue biopsy …